K Scotlandi

Summary

Affiliation: Istituti Ortopedici Rizzoli
Country: Italy

Publications

  1. ncbi Prognostic and therapeutic targets in the Ewing's family of tumors (PROTHETS)
    P Picci
    Istituti Ortopedici Rizzoli, Bologna, Italy
    Adv Exp Med Biol 587:1-12. 2006
  2. ncbi Targeted therapies in bone sarcomas
    K Scotlandi
    Laboratory of Oncologic Research, Istituto Ortopedico Rizzoli, Bologna, Italy
    Curr Cancer Drug Targets 9:843-53. 2009
  3. ncbi Designing novel therapies against sarcomas in the era of personalized medicine and economic crisis
    Maria Cristina Manara
    Development of Biomolecular therapies, Experimental Oncology Lab, Rizzoli Institute, Bologna, Italy
    Curr Pharm Des 19:5344-61. 2013
  4. doi Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma
    Cecilia Garofalo
    Centro Riferimento Specialistico Development of Biomolecular Therapies, Experimental Oncology Laboratory, Rizzoli Orthopedic Institute, 40136 Bologna, Italy
    Mol Endocrinol 26:1603-16. 2012
  5. pmc An integrated analysis of miRNA and gene copy numbers in xenografts of Ewing's sarcoma
    Neda Mosakhani
    Department of Pathology, Haartman Institute and HUSLAB, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    J Exp Clin Cancer Res 31:24. 2012
  6. pmc Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors
    Suvi Savola
    Department of Pathology, Haartman Institute and HUSLAB, University of Helsinki, Helsinki, Finland
    BMC Cancer 9:17. 2009
  7. ncbi Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells
    Katia Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, 40136 Bologna, Italy
    Clin Cancer Res 8:3893-903. 2002
  8. doi Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival
    Katia Scotlandi
    Laboratory of Experimental Oncology, Orthopaedic Institute Rizzoli, Bologna, Italy
    Eur J Cancer 47:1258-66. 2011
  9. ncbi Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors
    Katia Scotlandi
    Laboratory of Oncologic Research, Orthopaedic Rizzoli Institute, Bologna, Italy
    Cancer Res 65:3868-76. 2005
  10. doi Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome
    Katia Scotlandi
    Laboratory of Oncologic Research, Orthopaedic Institute Rizzoli, Via Di Barbiano 1 10, 40136 Bologna, Italy
    J Clin Oncol 27:2209-16. 2009

Collaborators

Detail Information

Publications63

  1. ncbi Prognostic and therapeutic targets in the Ewing's family of tumors (PROTHETS)
    P Picci
    Istituti Ortopedici Rizzoli, Bologna, Italy
    Adv Exp Med Biol 587:1-12. 2006
    ..LSHC-CT-2004-503036. The research will concentrate on translating the knowledge being created by genomics and other fields of basic research into applications that improve clinical practice and public health...
  2. ncbi Targeted therapies in bone sarcomas
    K Scotlandi
    Laboratory of Oncologic Research, Istituto Ortopedico Rizzoli, Bologna, Italy
    Curr Cancer Drug Targets 9:843-53. 2009
    ..The review identifies questions and concerns that still need to be addressed before proceeding to safe clinical trials with agents against these promising new targets...
  3. ncbi Designing novel therapies against sarcomas in the era of personalized medicine and economic crisis
    Maria Cristina Manara
    Development of Biomolecular therapies, Experimental Oncology Lab, Rizzoli Institute, Bologna, Italy
    Curr Pharm Des 19:5344-61. 2013
    ..Strategies considering the system in its complex are encouraged and, in this context, drugs aimed at reducing circulating insulin levels, such as metformin, should receive attention as potential anti-cancer agents. ..
  4. doi Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma
    Cecilia Garofalo
    Centro Riferimento Specialistico Development of Biomolecular Therapies, Experimental Oncology Laboratory, Rizzoli Orthopedic Institute, 40136 Bologna, Italy
    Mol Endocrinol 26:1603-16. 2012
    ....
  5. pmc An integrated analysis of miRNA and gene copy numbers in xenografts of Ewing's sarcoma
    Neda Mosakhani
    Department of Pathology, Haartman Institute and HUSLAB, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    J Exp Clin Cancer Res 31:24. 2012
    ..Xenografts have been shown to provide a suitable source of tumor tissue for molecular analysis in the absence of primary tumor material. We utilized ES xenograft series for integrated microarray analyses to identify novel biomarkers...
  6. pmc Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors
    Suvi Savola
    Department of Pathology, Haartman Institute and HUSLAB, University of Helsinki, Helsinki, Finland
    BMC Cancer 9:17. 2009
    ..Our genome-wide high-resolution analysis aspired to pinpoint genomic regions of highest interest and possible target genes in these areas...
  7. ncbi Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells
    Katia Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, 40136 Bologna, Italy
    Clin Cancer Res 8:3893-903. 2002
    ..In this study, we analyzed the preclinical effectiveness of this drug in osteosarcoma and Ewing's sarcoma...
  8. doi Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival
    Katia Scotlandi
    Laboratory of Experimental Oncology, Orthopaedic Institute Rizzoli, Bologna, Italy
    Eur J Cancer 47:1258-66. 2011
    ..We evaluated the expression of insulin-like growth factor (IGF)-receptor (IGF-IR), insulin receptor (IR), IGF-I and some major intracellular mediators (IRS1, p-ERK) in specimens from EWS patients with primary localised untreated tumours...
  9. ncbi Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors
    Katia Scotlandi
    Laboratory of Oncologic Research, Orthopaedic Rizzoli Institute, Bologna, Italy
    Cancer Res 65:3868-76. 2005
    ..For the broadest applicability and best efficacy in sarcomas, NVP-AEW541 may be combined with vincristine, actinomycin D, and ifosfamide, three major drugs in the treatment of sarcomas...
  10. doi Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome
    Katia Scotlandi
    Laboratory of Oncologic Research, Orthopaedic Institute Rizzoli, Via Di Barbiano 1 10, 40136 Bologna, Italy
    J Clin Oncol 27:2209-16. 2009
    ..In this study, we analyzed the molecular factors governing EWS response to chemotherapy to identify genetic signatures to be used for risk-adapted therapy...
  11. doi Targeting insulin-like growth factor 1 receptor in sarcomas
    Katia Scotlandi
    Laboratory of Oncologic Research, Istituti Ortopedici Rizzoli, Bologna, Italy
    Curr Opin Oncol 20:419-27. 2008
    ....
  12. ncbi C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions
    Katia Scotlandi
    Laboratorio di Ricerca Oncologica and Servicio di Anatomia Patologica, Istituti Ortopedici Rizzoli, Via Di Barbiano 1 10, 40136 Bologna, Italy
    J Clin Oncol 21:1952-60. 2003
    ..Autocrine/paracrine stimulation of c-kit has been recently observed in Ewing's sarcoma (ES) cell lines. In this study, we tested the prognostic and therapeutic role of the receptor in this tumor...
  13. ncbi Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells
    Katia Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Cancer 101:11-6. 2002
    ....
  14. ncbi Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells
    Katia Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Cancer Gene Ther 9:296-307. 2002
    ..These results indicate that inhibiting IGF-IR by antisense strategies may be relevant to the clinical treatment of ES patients by reducing the malignant potential of these cells and enhancing the effectiveness of chemotherapy...
  15. ncbi Targeted therapies in Ewing's sarcoma
    Katia Scotlandi
    Growth Factors and Receptors, Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Via Di Barbiano 1 10, 40136 Bologna, Italy
    Adv Exp Med Biol 587:13-22. 2006
    ..Toxic effects of these tailored therapies were also considered to offer the necessary rationale for the application of possible forthcoming clinical trials...
  16. ncbi CD99 engagement: an effective therapeutic strategy for Ewing tumors
    K Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Cancer Res 60:5134-42. 2000
    ..These results provide a novel entry site for therapeutic intervention, which may have application in the care of patients with Ewing tumor, and warrant additional studies to clarify the molecular mechanisms activated by CD99 engagement...
  17. ncbi Murine model for skeletal metastases of Ewing's sarcoma
    K Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Universita degli Studi di Bologna, Italy
    J Orthop Res 18:959-66. 2000
    ..This experimental model of bone metastasis of Ewing's sarcoma may be the basis for future studies aimed at understanding the pathophysiology and treatment of Ewing's sarcoma...
  18. ncbi Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma
    Katia Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Via Di Barbiano 1 10, 40136 Bologna, Italy
    Eur J Cancer 41:1349-61. 2005
    ..Therefore, the therapeutic potential of trastuzumab in these neoplasms may be better exploited in combined treatments with anti-IGF-IR approaches...
  19. ncbi Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma
    Katia Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna 40136, Italy
    Eur J Cancer 42:91-6. 2006
    ..These results provide the necessary rationale and support for a novel modality of therapeutic intervention, which may have application in the care of patients with ES...
  20. ncbi CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity
    K Scotlandi
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Oncogene 26:6604-18. 2007
    ..In addition, a dualistic role for the two CD99 isoforms was shown in agreement with what was observed for other cell adhesion molecules...
  21. ncbi The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71
    M C Manara
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, I 40136 Bologna, Italy
    Int J Oncol 27:1605-16. 2005
    ....
  22. ncbi Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells
    S Benini
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, 40136 Bologna, Italy
    Clin Cancer Res 7:1790-7. 2001
    ..In conclusion, we showed that, in ES, the blockage of IGF-IR by a neutralizing MAb or by suramin may greatly potentiate the antitumor activity of conventional chemotherapeutic drugs...
  23. doi Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma
    I Scionti
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Ann Oncol 19:1500-8. 2008
    ..C-MYC and DHFR protein levels at diagnosis were assessed by immunohistochemistry on series of patients treated with either a MTX-based protocol (IOR/OS-1; 72 patients) or with a standard four-drug regimen (ISG/SSG 1; 61 patients)...
  24. ncbi Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells
    R Strammiello
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Horm Metab Res 35:675-84. 2003
    ..Taken together, these findings add a new activity to the IGF-I repertoire in ES and highlight how disruption of IGF-IR functions may constitute an effective tool for the control of neovascularization in this tumor...
  25. ncbi P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy
    N Baldini
    Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, University of Bologna, Italy
    J Orthop Res 17:629-32. 1999
    ..Standard programs are sufficient for P-glycoprotein-negative osteosarcomas, whereas P-glycoprotein-positive tumors may benefit from the use of more intensive therapeutic approaches...
  26. ncbi Identification of EWS/FLI-1 transcripts in giant-cell tumor of bone
    K Scotlandi
    Laboratorio di Ricerca Oncologica, Dipartimento Goidanich, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Cancer 87:328-35. 2000
    ..Detection of EWS/FLI-1 fusion transcripts in giant-cell tumor of bone provides a model for the study of the transforming mechanisms of the EWS/FLI-1 fusion gene in mesenchymal tumors...
  27. ncbi Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells
    M C Manara
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, I 40136 Bologna, Italy
    Int J Oncol 24:365-72. 2004
    ..Therefore, our data support the use of IFNalpha or IFNbeta in the treatment of osteosarcoma patients who overexpress P-glycoprotein in their primary tumors, and respond insufficiently to current therapeutic regimens...
  28. ncbi Simultaneous paired analysis of numerical chromosomal aberrations and DNA content in osteosarcoma
    M Serra
    Laboratorio di Ricerca OncologicaIstituti Ortopedici Rizzoli, Bologna, Italy
    Mod Pathol 14:710-6. 2001
    ....
  29. doi Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines
    Claudia M Hattinger
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Genes Chromosomes Cancer 48:289-309. 2009
    ..These results indicate that resistance to DX and MTX in human OS cell lines is a multigenic process involving gene copy number and expression changes...
  30. ncbi Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells
    C Ricci
    Institute for Cancer Research, University of Bologna, Bologna, Italy
    Int J Cancer 87:29-36. 2000
    ..In 3 of 3 human rhabdomyosarcoma cell lines positive for both HER-2 and HER-3 receptors, the treatment with GGF-2 induced a significant increase in myogenic differentiation...
  31. pmc CD99 acts as an oncosuppressor in osteosarcoma
    Maria Cristina Manara
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, 40136 Italy
    Mol Biol Cell 17:1910-21. 2006
    ..The findings point to an antioncogenic role for CD99 in osteosarcoma, likely through the regulation of caveolin-1 and inhibition of c-Src kinase activity...
  32. ncbi Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells
    M Serra
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Ann Oncol 15:151-60. 2004
    ..To evaluate the impact of dihydrofolate reductase (DHFR) and reduced folate carrier (RFC) genes on methotrexate (MTX) resistance in osteosarcoma cells in relation to retinoblastoma (RB1) gene status...
  33. doi Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma
    Michela Pasello
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Cancer Res 68:6661-8. 2008
    ....
  34. pmc CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis
    Anna Rocchi
    Laboratory of Experimental Oncology, CRS Development of Biomolecular Therapies, SSN Emilia Romagna Istituti Ortopedici Rizzoli IRCCS, Bologna, Italy
    J Clin Invest 120:668-80. 2010
    ..Together, these data indicate a new role for CD99 in preventing neural differentiation of EWS cells and suggest that blockade of CD99 or its downstream molecular pathway may be a new therapeutic approach for EWS...
  35. ncbi Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects
    Stefania Benini
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Cancer 108:358-66. 2004
    ..Our findings therefore identify MAPK pathway as a promising target for pharmacologic intervention in ES...
  36. ncbi 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients
    Michela Pasello
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Via Di Barbiano 1 10, 40136 Bologna, Italy
    Eur J Cancer 41:2184-95. 2005
    ....
  37. ncbi Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma
    Stefania Benini
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Cancer 119:1039-46. 2006
    ..IGFBP-3 acts mainly through IGF-dependent mechanisms and the protein may therefore represent an alternative strategy to inhibit IGF-IR functions. The data indicate IGFBP-3 as a molecule of therapeutic potential in EWS...
  38. doi Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target
    Maria A Pantaleo
    Department of Hematology and Oncology Sciences L A Seragnoli, Sant Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Int J Cancer 125:2991-4. 2009
    ..Both young adult with WT GIST had the over-expression of IGF1R at mRNA and protein level. These results further confirm the hypothesis that IGF1R may be a potential therapeutic target in GISTs lacking KIT and PDGFRA mutations...
  39. pmc Prelamin A-mediated recruitment of SUN1 to the nuclear envelope directs nuclear positioning in human muscle
    E Mattioli
    Institute for Molecular Genetics, IGM CNR, Unit of Bologna, Bologna, Italy
    Cell Death Differ 18:1305-15. 2011
    ..These results demonstrate that the interplay between SUN1 and farnesylated prelamin A contributes to nuclear positioning in human myofibers and may be implicated in pathogenetic mechanisms...
  40. doi Prognostic value of CCN3 in osteosarcoma
    Bernard Perbal
    Laboratorio di Ricerca Oncologica and Laboratorio di Rigenerazione Tissutale Ossea, Istituti Ortopedici Rizzoli, Bologna, Italy
    Clin Cancer Res 14:701-9. 2008
    ..We assessed the prognostic value of CCN1, CCN2, and CCN3 genes, involved in fundamental biological processes...
  41. pmc The expression of ccn3(nov) gene in musculoskeletal tumors
    Maria Cristina Manara
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Am J Pathol 160:849-59. 2002
    ..Further studies will help to clarify the biological role of this protein in musculoskeletal neoplasms...
  42. doi NVP-BEZ235 as a new therapeutic option for sarcomas
    Maria C Manara
    Laboratorio di Ricerca Oncologica, Istituto Ortopedico Rizzoli, Bologna, Italy
    Clin Cancer Res 16:530-40. 2010
    ..To evaluate the in vitro and in vivo effects of NVP-BEZ235, a dual pan-phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor in the three most common musculoskeletal tumors (osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma)...
  43. doi Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP)
    Diana Zambelli
    Laboratory of Oncologic Research, Istituti Ortopedici Rizzoli, Bologna, Italy
    Int J Cancer 126:41-52. 2010
    ..Thus, we propose LGALS3BP as a novel reliable indicator of prognosis, and we offer genetic signatures to the scientific communities for cross-validation and meta-analysis, which are indispensable tools for a rare tumor such as EWS...
  44. pmc Treatment of nonmetastatic Ewing's sarcoma family tumors of the spine and sacrum: the experience from a single institution
    Gaetano Bacci
    Sezione di Chemioterapia, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
    Eur Spine J 18:1091-5. 2009
    ..We concluded that regardless of the type of local treatment even when associated with neoadjuvant therapy, ESFT in the spine and sacrum has a poor outcome and prognosis is significantly worse than that of primary ESFT in other sites...
  45. ncbi Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques
    Claudia M Hattinger
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Eur J Cell Biol 82:483-93. 2003
    ..These data demonstrate that genetic analyses with complementary techniques are helpful for the identification of new candidate genes, which might be considered for an early identification of MTX unresponsive tumors...
  46. doi Caveolins in the development and diseases of musculoskeletal system
    Massimo Serra
    Department of Musculoskeletal Oncology, Oncologic Research Laboratory, Servizio Sanitario Regionale Emilia Romagna, Istituto Ortopedici Rizzoli, IRCCS, Via Di Barbiano 1 10, 40136 Bologna, Italy
    Cancer Lett 284:113-21. 2009
    ..This brief review is focused on the role of caveolins in the physiology and pathology of musculoskeletal system and will discuss the key features of caveolins as related to differentiation and diseases of bone and muscle cells...
  47. ncbi Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities
    Massimo Serra
    Laboratorio di Ricerca Oncologica, Sezione di Chemioterapia, Servizio di Anatomia Patologica, Va Divisione, and Unita di Chirurgia Generale, Istituti Ortopedici Rizzoli, Bologna, Italy
    J Clin Oncol 21:536-42. 2003
    ..To evaluate the prognostic value of P-glycoprotein and clinicopathologic parameters in a large series of high-grade osteosarcoma (OS) patients treated at the Rizzoli Institute...
  48. doi Prognostic relevance of CCN3 in Ewing sarcoma
    Bernard Perbal
    Rizzoli Orthopaedic Institute, Bologna, Italy
    Hum Pathol 40:1479-86. 2009
    ..We hypothesize that the increased level of variant CCN3 in the tumor cells reduces their tumorigenic potential and results in better outcome...
  49. ncbi May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol
    Massimo Serra
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, 40136 Bologna, Italy
    Int J Oncol 29:1459-68. 2006
    ..P-glycoprotein evaluation can therefore constitute the basis for stratifying, at diagnosis, osteosarcoma patients for whom alternative treatments may be considered...
  50. ncbi Genetic analysis of fibrosarcoma of bone, a rare tumour entity closely related to osteosarcoma and malignant fibrous histiocytoma of bone
    Claudia Maria Hattinger
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Eur J Cell Biol 83:483-91. 2004
    ..Moreover, these findings suggest the possible presence of an autocrine loop in FS of bone, which might be taken into account for planning innovative therapeutic strategies for patients unresponsive to conventional treatments...
  51. ncbi In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type
    Stefania Benini
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, 40136 Bologna, Italy
    Oncogene 24:4349-61. 2005
    ..However, the underlying molecular mechanisms appear to be different, further highlighting the importance of the cellular context in the regulation of function of CCN proteins...
  52. ncbi Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma
    Maria C Manara
    Laboratory of Oncologic Research, Istituti Ortopedici Rizzoli, Bologna, Italy
    Clin Cancer Res 13:1322-30. 2007
    ..NVP-AEW541 seems one of the most promising agents. In this article, we point out its effects against migration, metastasis, vasculogenicity, and angiogenesis of Ewing's sarcoma cells...
  53. doi CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity
    C Zucchini
    Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
    Oncogene 33:1912-21. 2014
    ....
  54. doi Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling
    C Garofalo
    Laboratory of Experimental Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Oncogene 30:2730-40. 2011
    ..Moreover, we provide evidences supporting IR-A as an important target in sarcoma therapy...
  55. ncbi Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators
    Vanessa Cerisano
    Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna 40136, Italy
    Oncogene 23:5664-74. 2004
    ..Therefore, our findings indicate that CD99 functions occur through reorganization of cytoskeleton and identify actin and zyxin as the early signaling events driven by CD99 engagement...
  56. ncbi Expression profiling of osteosarcoma cells transfected with MDR1 and NEO genes: regulation of cell adhesion, apoptosis, and tumor suppression-related genes
    Marta Sanchez-Carbayo
    Memorial Sloan Kettering Cancer Center, Albert Einstein College of Medicine, York, New York 10021, USA
    Lab Invest 83:507-17. 2003
    ..This study further elucidates the genetic events associated with MDR1 expression and identifies novel targets associated with multidrug resistance...
  57. ncbi Intracellular pH regulation in U-2 OS human osteosarcoma cells transfected with P-glycoprotein
    Anna Maria Porcelli
    Dipartimento di Biologia Evoluzionistica Sperimentale, Universita di Bologna, Italy
    Biochim Biophys Acta 1542:125-38. 2002
    ....
  58. ncbi Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma
    Nadia Coltella
    Laboratory of Cancer Genetics, Institute for Cancer Research and Treatment IRCC, Strada Provinciale 142, Km 3 95, 10060 Candiolo To, Italy
    FASEB J 17:1162-4. 2003
    ..These data show that HGF activates both the mitogen and motogen machinery in osteosarcoma cells and suggest that HGF might promote their malignant behavior by concomitant activation of different pathways and biological functions...
  59. ncbi Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling
    Lara Cantiani
    Laboratory of Oncology Research, Rizzoli Orthopaedic Institute, Italy
    Cancer Res 67:7675-85. 2007
    ..These data strengthen the rationale to target c-Src family kinases and/or Met receptor to improve the extremely poor prognosis of metastatic osteosarcoma...
  60. ncbi Apoptotic genes as potential markers of metastatic phenotype in human osteosarcoma cell lines
    Cinzia Zucchini
    Dipartimento di Istologia, Embriologia e Biologia Applicata, Universita di Bologna, 40126 Bologna, Italy
    Int J Oncol 32:17-31. 2008
    ..Hence, we propose the inhibition of the NF-kappaB pathway as a rational strategy for effective management of human osteosarcoma...
  61. ncbi Differentially expressed genes in multidrug resistant variants of U-2 OS human osteosarcoma cells
    Tokuhiro Chano
    Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Tsukinowa cho, Seta, Otsu, Shiga 520 2192, Japan
    Oncol Rep 11:1257-63. 2004
    ..Molecular and biological characterization of these genes will yield further insight into the features between MDR and tumor progression in human osteosarcomas...
  62. ncbi Identification of candidate genes involved in the reversal of malignant phenotype of osteosarcoma cells transfected with the liver/bone/kidney alkaline phosphatase gene
    Cinzia Zucchini
    Centro di Ricerca in Genetica Molecolare Fondazione CARISBO at the Istituto di Istologia ed Embriologia Generale, University of Bologna, Italy
    Bone 34:672-9. 2004
    ....
  63. ncbi Different simian virus 40 genomic regions and sequences homologous with SV40 large T antigen in DNA of human brain and bone tumors and of leukocytes from blood donors
    Fernanda Martini
    Department of Morphology and Embryology, Section of Histology and Embryology, University of Ferrara, Ferrara, Italy
    Cancer 94:1037-48. 2002
    ..Many studies found only a small fragment of the large T-antigen coding sequences in human tumors, raising doubts on authenticity of SV40 sequences detected in these samples...